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Abstract: The aim of the study is to describe the radiological imaging
features of different solitary fibrous tumors (SFTs) locations and present
histopathological correlations.
From 2007 to 2013, 20 cases of histologically confirmed that
SFTs were retrospectively analyzed with computed tomography (CT;
9/20), magnetic resonance imaging (MRI; 5/20), or both CT and MRI
(6/20).
All 20 SFTs were well defined, lobular, soft-tissue masses, and 60%
were located outside of the pleura. One pleural case invaded to the 10th
thoracic vertebra and had lung metastases. Images revealed 11 hetero-
geneous lesions that exceeded 3.0 0.203 cm along the greatest axis
with patchy necrotic foci, and 9 homogeneous lesions <3.0 0.203.
Microscopically, all SFTs were proliferative spindle cells with varying
degrees of fibrosis and interspersed vessel branching. Cells were
strongly immunopositive for CD34.
Here we review variable imaging findings of SFTs, which can be
within the pleura as well as within other serosal tissues such as the
meninges and postperitoneum. SFTs > 3.0 0.203 cm along the great-
est axis appeared to be mixed patterns, whereas SFTs < 3.0 0.203 cm
had isodense appearances. SFTs cells were CD34 immunopositive and
surgery was a first-line treatment choice.
(Medicine 95(13):e3031)
Abbreviations: Bcl-2 = B-cell lymphoma protein 2, CT =
computed tomography, EMA = endosomal membrane, H&E =
hematoxylin and eosin, hypo = hypointense, iso = isointense, MRI
= magnetic resonance imaging, SFTs = solitary fibrous tumors,d Ni Yicheng, PhD
KEY POINTS
We depict variable imaging finding of SFTs.
60% of SFTs are not within pleura but in other locations.
SFTs > 3.0 0.203 cm to be mixed patterns.
SFTs < 3.0 0.203 cm had isodense appearances.
SFTs cells were CD34 immunopositive.
INTRODUCTION
S olitary fibrous tumors (SFTs) are rare mesenchymal tumorsthat typically originate from the pleura and pelvis.1,2 His-
topathologic characteristics of SFTs were first described by
Klemperer and Rabin in 1931 as pleura-localized fibrous
mesotheliomas.3,4 Reports suggest that SFTs also originate
from extrapleural sites such as the pelvis, abdomen, retroperito-
neum, buccal space, maxillary sinus, liver, pancreas, suprarenal
region, and kidneys.4–10 An SFTs diagnosis is characterized by
the proliferation of spindle mesenchymal cells and positive
immunohistochemical staining for CD34.11,12 Approximately
78% to 88% of SFTs are benign, but 12% to 22% are malig-
nant.13,14 The age-standardized incidence of SFTs is reported to
be 1.4 per million15 and their rarity, diverse localizations, and
difficulty of predicating tumor biological behaviors have limited
the attempts to obtainCTandMRI data to better characterize their
features. Thus, more and larger population studies with CT and
MRI are required to enrich our understanding on this tumor typemprove diagnosis andmanagement.Here,
we report data from 20 patients with both benign and aggressive
SFTs at various sites.
MATERIALS AND METHODS
From our hospital’s pathology database, we identified
patients diagnosed with SFTs between January 2007 and June
2013. All 20 patients with SFTs who underwent preoperative
CT or MRI were included in this study. An institutional review
board exemption and a waiver for the requirement of written
informed consent were obtained to perform this retrospective
study. Of the 20 patients, 9 had been examined with computed
tomography (CT), 5 had undergone magnetic resonance ima-
ging (MRI), and 6 had both CT and MRI.
CT imaging was performed using a 128-multidetector row
scanner (SOMATOM Definitions AS 128, Siemens). Scan
parameters were as follows: 5-mm slice thickness reconstruc-
tions, 36 36 cm field-of-view, 120 kV voltages, 100 to 220mA12 matrix. Contrast-enhanced CT scans
d 60 s after contrast agent (Omnipaque,
injection.
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MRIwasperformedusinga 3.0TMRI (Verio 3.0T, Siemens)
or a 1.5T MRI unit (Gyroscan Intera; Philips Medical Systems,
Best, The Netherlands). The MRI protocol included axial
T1-weighted imaging (T1WI) sequences; axial and sagittal T2-
weighted imaging (T2WI) sequences; and contrast-enhanced
axial, sagittal, and coronal T1WI sequences (fat suppressed).
An intravenous dose of 0.1 to 0.2mmol/kg of contrast agent
(gadolinium-DTPA, Schering, location) was administered to
patients undergoing contrast-enhanced MR scanning.
All medical records from 20 patients were reviewed and
patient age, sex, initial symptoms, treatment, follow-up ima-
ging, and outcome were registered. CT and MRI images were
reviewed independently by 2 experienced radiologists. Dis-
agreements over imaging findings were resolved by debate,
discussion, and consensus between the 2 radiologists. Imaging
features of each scan were recorded for lesion location, shape,
size, and number, intensity of unenhanced and contrast-
enhanced lesions and classified as hypo-, iso-, or hyperintense
with respect to the adjacent tissues.
Of the 20 cases, 1 had a biopsy and no additional interven-
tion; 5 subjects underwent surgery; and 14 had biopsies before
surgery. All pathologic specimens were reviewed and described
by 2 experienced pathologists. Histological techniques included
staining with hematoxylin and eosin (H&E) and immunohisto-
chemical analyses including staining for CD34, CD99, B-cell
lymphoma protein 2 (Bcl-2), ki67, vimentin, S-100 protein,
cytokeratin (CK), and smooth muscle actin (SMA).
Numerical data such as the size of tumor at CT or MRI
measured at the contrast-enhanced images of each transaxial
section were averaged for each patient and descriptively com-
pared among patients. We used the receiver operating charac-
teristic (ROC) curve to determine the best cut-off values of the
standard for sensitivity and specificity imaging features of
SFTs. All descriptive and statistical analyses were performed
using the Statistical Package for the Social Sciences (SPSS
Zhanlong et alversion 16.0; Chicago, IL). Variables are presented with stan-
Pathological and Immunohistochemical Findings
Microscopically, all SFTs were patternless distributed
proliferating spindle cells with varying degrees of fibrosis
FIGURE 1. Receiver operating characteristic (ROC) curve. The
SFTs imaging features were classified with homogeneous anddard errors (SE) and high-quality authentic CT and MRI scans
and histopathological findings are presented.
RESULTS
Clinical Data
We included 20 subjects (12 men; mean age 43.2 years;
range 31–71 years). Of the 8 patients with pleural SFTs (40%),
3 had chest pain; 4 patients were admitted for routine check-ups;
and 1 patient had spine pain. Sixty percent of SFTs were located
beyond the pleura and 3 brain SFTs occurred in patients who
complained of dizziness and an unstable gait. Then, 3 renal
SFTs were found and 1 was located in the posterior peritoneal
are and 2 were pancreatic SFTs identified during a routine
check-up. One pelvic SFT occurred in a subject who had urinary
frequency, and 1 esophageal SFTwas identified in a patient who
had difficulty swallowing. Finally 1 orbital SFT was identified
in a patient with vision loss.
Imaging Findings
Imaging findings all 20 subjects with SFT were as follows:
19 were well-defined, noninvasive, lobular, soft-tissue masses
with displaced and compressed neighboring tissues. One malig-
nant pleural SFT had invaded to the T10 vertebra and there were
lung metastases confirmed with CT. CT and MRI images
revealed heterogeneous masses with patchy, necrotic foci in
11 lesions exceeding 3.0 0.203 cm along the greatest axis, and
2 | www.md-journal.comhomogeneous masses in 9 lesions <3.0 0.203 cm along the
greatest axis. The area under the receiver operating character-
istic (ROC) curve calculated using the greatest axis of SFTs is
shown in Figure 1 for each of the cohorts and for the overall
patient sample, in which the area under the curve (AUC) was
0.95 (95% confidence interval, 2.98–3.03).
For the larger SFTs, enhancement after contrast injection
was typically intense and heterogeneous with central areas of
low attenuation that correlated with necrosis, hemorrhage, or
cystic degeneration. These SFTs are well-delineated and lobu-
lated soft tissue masses (Figure 2). Smaller masses were chiefly
intense and homogeneous after contrast medium enhancement.
Solid masses with smoothly tapering margins were highly
characteristic of these tumors (Figure 3) and calcification
was not observed in any SFT in this study.
One case of pleural malignant SFT was well-defined
and solid, 3.2  2.6 cm in diameter on CT scans. The tumor
originated from the pleura and spread to the T10 vertebra and
had metastatic foci in the lung. There were no mediastinal
lymph node swelling and no liver metastases (Figure 4).
Three patients had extremely rare SFTs of the pancreas,
esophagus, and orbit (Figure 5). CT scans revealed a
4.3 4.6 cm, well-defined heterogeneous mass with patchy,
necrotic foci in the pancreatic head. Contrast-enhanced CT
images showed heterogeneous enhancement with patchy hypo-
dense areas in both the arterial (Figure 5A) and the venous
(Figure 5A’) phases with no signs of pancreatic duct obstruction
or jaundice. The esophageal SFT was a 1.8  2.0 cm homo-
geneous mass located in the lower end of the esophagus
(Figure 5B), which was mildly enhanced after contrast admin-
istration (Figure 5B’). For the orbital SFT, T1-weighted MRI
revealed a nearly homogeneous lesion (Figure 5C), which had
strong but heterogeneous contrast enhancement (Figure 5C’).
Medicine  Volume 95, Number 13, April 2016heterogeneous enhancement. The ROC curve showed in
3.00.203 cm of the tumor great size; the homogeneous and
heterogeneous enhancement sensitivity and specificity were 0.95,
respectively. ROC¼ receiver operating characteristic.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Typical features of larger SFTs. A, A’: A 35-year-oldman with an incidental finding of SFT. Parenchymal (A) andmediastinal (A’)
contrast material-enhanced CT images showed a round solitary fibrous tumor of the pleura. B, B’: A 54-year-old male presented with a
pelvic SFT. Contrast-enhanced CT image (B, axial) and (B’ coronal) views reveal an oval, well-defined heterogeneous mass with patchy
hyperdense (tumor tissue, arrow) and hypodense (necrotic tissue, curved arrow) areas and marked heterogeneous enhancement.
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Medicine  Volume 95, Number 13, April 2016 CT and MR Imaging Features of SFTsand interspersed vessel branching. There were no distinctive
microscopic features, so separating SFT from other spindle cell
tumors using by H&E staining alone is problematic. Immuno-
histochemically, SFTs were strongly immunopositive for CD34
(Figure 6). Ki67 was positively expressed in nearly 10% of
SFTs and vimentin and CD99 were expressed in most SFTs.
C, C’: A 41-year-old female patient with a brain SFT. MR T2-weight
the occipital lobe (C). Contrast-enhanced T1-weighted images sho
tomography, MR¼magnetic resonance, SFTs¼ solitary fibrous tumHowever, SFTs were typically immunonegative for Bcl-2,
SMA, CKpan, S-100, and endosomal membrane (EMA) protein
(Table 1).
DISCUSSION
SFTs are extremely rare mesenchymal spindle cell neo-
plasms that most commonly occur in the pleura or other serosal
surfaces and the histological origins are uncertain. Histopatho-
logically, SFTs have a ‘‘patternless’’ architecture characterized
by the coexistence of hypo- and hypercellular areas separated by
fibrous stroma having ‘‘hemangiopericytoma-like’’ branching
blood vessels. A final diagnosis is often made with immuno-
histochemical findings. Immunopositivity for CD34 is the key
to SFTs diagnosis and positive expression of vimentin; CD99
and Bcl-2 occur in most SFTs. However, cytokeratin, a-SMA,
and S-100 are usually absent.11,12
Submesothelial cells can differentiate into mesothelial
cells, so SFTs occur at often-overlooked sites.16 In this study,
we identified 20 patients diagnosed with SFTs between January
2007 and June 2013 and of these subjects 60% of SFTs were
outside of the pleura and histopathology confirmed that SFTs
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.were well-established and generally benign. These SFTs were
strongly immunopositive for CD34, and CD99 was most posi-
tively expressed; Ki67 was expressed in 10% of SFTs. Tumors
were immunonegative for Bcl-2, SMA, CKpan, S-100, and
EMA protein (Table 1).
CT or MRI helps to identify SFTs and often reveals
proliferation of fibrous tissues as well as tumor and adjacent
tissue details to facilitate decisions for surgical tumor
removal.17 Still, CT and MRI features of SFTs are nonspecific,
revealing well-defined and often lobulated soft tissue space-
occupying masses that displace adjacent anatomic struc-
tures.18,19 For our 20 cases, 12/20 patients with SFTs who were
diagnosed in our single hospital were located in extrapleural
sites (60%). SFTs of different sizes had different features
according to CT and MRI.
In the field of medical diagnosis, receiver operating
characteristic (ROC) curves have become the standard tool
for assessment of predictive accuracy. In this study, we used
ROC curve to determine the best cut-off values of the standard
for sensitivity and specificity imaging features of SFTs. With
the ROC curve analysis, the area under the curve (AUC) was
0.95 (95% confidence interval, 2.98–3.03). The larger SFTs
(3.0 0.203 cm) were heterogeneous masses with patchy,
necrotic foci, and smaller SFTs (3.0 0.203 cm) were
homogeneous masses.
images revealed a heterogeneous hypo- and hyperintense mass in
d heterogeneous enhancement of the lesion (C’). CT¼computed
s.Unenhanced CT images revealed larger SFTs were iso-
dense relative to muscle and some contained hypodense areas
representing necrotic, myxoid, or cystic changes. With MRI,
www.md-journal.com | 3
retrospective study with SFTs patients who underwent MRI in
FIGURE 3. Typical features of small SFTs. A, A’: A 43-year-old man with parenchymal (A) and mediastinal windows (A’) of the CT scan
showed a round solitary fibrous tumor of the pleura (2.82.3 cm). B, B’: A 48-year-old female patient presented with a right kidney
solitary fibrous tumor. Arterial (B) and portovenous (B’) phases of contrast-enhanced CT showed a spherical, well-defined homogeneous
mass withmarked homogeneous enhancement. C, C’: A 68-year-old female patient with brain SFT. AT1-weighted axial MRI scan revealed
). G
ted
Zhanlong et al Medicine  Volume 95, Number 13, April 2016T2WI of hypointense lesions were related to hypercellularity
and abundant collagenous stroma. Hyperintense lesions were
relative to necrotic, myxoid, or cystic changes. Enhanced CT or
MRI revealed mild to marked heterogeneous contrast uptake
correlating with hypocellularity or hypervascular areas, which
is consistent with previous reports.20,21
Mixed patterns were common in larger SFTs and smaller
SFTs were isodense or isointense in both on unenhanced and
enhanced CT andMRI.22 Unlike other reports,23,24 we observed
no calcification in any of the 20 cases in our study, suggesting
that this is uncommon in SFTs.
Most SFTs are benign but a few have histologically
malignant features such as increased cellularity with
crowded/overlapping nuclei, cellular pleomorphisms, and a
mitotic count of >4 dividing cells per 10 high-power fields.13
CT and MRI confirm that malignant mass edges had infiltrating
growths and hemorrhages or necrosis and lung metastasis were
also observed.25 Finally, clinical outcomes for malignant SFTs
are not always poor.26
To our knowledge, reports of SFTs from numerous extra-
pleural locations are most common in the literature and these
include localization to the retroperitoneal, intrameningeal, or
pelvic space; the thyroid or mammary gland; the cervical spine,
the orbital space, and in the extremities.27,28 Of identified
a large lobulated hypointense mass (arrow) in the left cerebellum (C
and homogeneous enhancement of the mass (arrow). CT¼compu
fibrous tumors.20 patients with SFTs, 60% were extrapleural.
The findings of SFTs on CT and MRI are generally
nonspecific for pathognomonic diagnosis. Differential
4 | www.md-journal.comdiagnosis of STF includes localization to the pleura for
mesotheliomas, to the brain for dural-based meningiomas or
hemangiopericytomas, to the abdomen for interstitialomas, and
to the kidney for angiomyolipomas, and so on.29–31 Diagnoses
should be considered along with evidence from CT and MRI,
histopathological findings, and CD34 immunoreactivity data.
Surgical resection is the best long-term cure and helps to
establish a confirmatory pathologic diagnosis for SFTs.
Like in every study, our study also has some limitations.
First, in such a long-time survey and using different imaging
techniques, it is difficult to maintain consistency. So, we have
not measured the CT or MRI intensities and have not done any
quantitative comparison because we have found that the SFTs
have not any typical feature of MRI intensities and the different
scanners with 1.5 and 3T. However, the typical dates such as the
size of tumor at CT or MRI measured at the contrast-enhanced
images of each transaxial section were averaged for each patient
and descriptively compared among patients. Second, this is a
adolinium-enhanced T1-weighted axial MRI (C’) showedmarked
tomography, MRI¼magnetic resonance imaging, SFTs¼ solitaryour single hospital with a period of time and further research in a
larger population is required to refine the imaging findings.
CONCLUSION
We describe variable imaging findings for SFTs from our
medical center. SFTs are rare tumors that occur postperitoneally
and in organs such as the kidney and pancreas. Approximately
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 4. Typical features of malignant SFTs. A mass was found that originated from the pleura and was metastasized to the lung. CT
mediastinal windows (A) showed a homogeneous lesion (curved arrow) in the left pleura invading to the neighboring T10 vertebral body
(arrow, confirmed pathology). Parenchymal windows (B) showed metastases (arrows) in the right lung. Lesions (arrows) are marked and
heterogeneously enhanced on T1-weighted MRI scans (C and D). CT¼computed tomography, MRI¼magnetic resonance imaging,
SFTs¼ solitary fibrous tumors.
FIGURE 5. Typical features of rare locations of SFTs. A, A’: A 71-year-oldmanwith a pancreatic SFT. Contrast-enhancedCTshowed an oval,
well-defined heterogeneousmass (arrows)withmarked heterogeneous enhancement (A, A’). B, B’: A 69-year-oldmanwith an esophageal
SFT. CT images before (B) and after (B’) contrast-enhancement showed an oval, well-defined homogeneous mass with marked
homogeneous enhancement (arrow). C, C’: A 57-year-old male patient with an orbital SFT. T1-weighted MRI scans before (C) and
after (C’) contrast-enhancement showed an oval, well-defined heterogeneous mass (arrow) with marked heterogeneous enhancement.
CT¼computed tomography, MRI¼magnetic resonance imaging, SFTs¼ solitary fibrous tumors.
Medicine  Volume 95, Number 13, April 2016 CT and MR Imaging Features of SFTs
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FIGURE 6. Histopathological views of SFTs. (A) Histomicrograph (H&E 200) showed that the SFT was composed of a patternless
proliferation of spindle cells with varying degrees of fibrosis. (B) A histomicrograph (200) depicts extensive immunopositive CD34
expression. SFTs¼ solitary fibrous tumors.
TABLE 1. Immunohistochemistry Findings of the 20 Cases With Solitary Fibrous Tumors
Location
Case
No
CD34
(þ/)
CD99
(þ/)
Ki67
(þ/)
Vim
(þ/)
Bcl-2
(þ/)
SMA
(þ/)
CKpan
(þ/)
S-100
(þ/)
EMA
(þ/)
Pleura 8 8/0 5/3 6/2 6/2 4/4 3/5 0/8 2/6 0/8
Kidney 3 3/0 2/1 3/0 2/1 0/3 0/3 1/2 0/3 0/3
Brain 3 3/0 2/1 2/1 3/1 1/2 1/2 0/3 1/2 0/3
Pelvis 1 1/0 1/0 1 1/0 0/1 0/1 0/1 0/1 0/1
Postperitoneum 1 1/0 0/1 1 1/0 0/1 0/1 1/0 0/1 0/1
Pancreas 2 2/0 1/1 1/1 2/0 0/2 0/2 0/2 0/2 0/2
Esophagus 1 1/0 1/0 0/1 1/0 0/1 0/1 0/1 0/1 0/1
Orbit 1 1/0 1/0 1/0 1/0 1/0 0/1 0/1 0/1 1/0
1
Zhanlong et al Medicine  Volume 95, Number 13, April 201660% of SFTs are not within the pleura. With the ROC
curve analysis, CT and MRI findings of mixed patterns
of SFTs > 3.0 0.203 cm at the greatest axis and SFTs
<3.0 0.203 cm at the greatest axis are isodense with
contrast enhancement. Thus, radiologists should be aware of
potential diagnoses of SFTs. A final diagnosis of SFT can be
Total 20 20/0 12/8 15/5
EMA¼ endosomal membrane.established by histological examination of tissue taken from
percutaneous biopsy or surgery, and surgery is the first treat-
ment choice.
REFERENCES
1. Harrison-Phipps KM, Nichols FC, Schleck CD, et al. Solitary fibrous
tumors of the pleura: results of surgical treatment and long-term
prognosis. J Thorac Cardiovasc Surg. 2009;138:19–25.
2. Bruzzone A, Varaldo M, Ferrarazzo C, et al. Solitary fibrous tumor.
Rare Tumors. 2010;2:e64.
3. Klemperer P, Rabin CB. Primary neoplasms of the pleura. A report
of five cases. Arch Pathol. 1931;11:385–412.
4. Gengler C, Guillou L. Solitary fibrous tumour and haemangioper-
icytoma: evolution of a concept. Histopathology. 2006;48:63–74.5. Rosado-de-Christenson ML, Abbott GF, McAdams HP, et al. From
the archives of the AFIP: localized fibrous tumor of the pleura.
Radiographics. 2003;23:759–783.
6 | www.md-journal.com6. Cuello J, Bruge´s R. Malignant solitary fibrous tumor of the kidney:
report of the first case managed with interferon. Case Rep Oncol
Med. 2013:564980.
7. Weon YC, Kim EY, Kim HJ, et al. Intracranial solitary fibrous
tumors: imaging findings in 6 consecutive patients. AJNR Am J
Neuroradiol. 2007;28:1466–1469.
8. Chen H, Xiao CW, Wang T, et al. Orbital solitary fibrous tumor: a
clinicopathologic study of ten cases with long-term follow-up. Acta
Neurochir (Wien). 2012;154:249–255.
9. Miyamoto H, Molena DA, Schoeniger LO, et al. Solitary fibrous
tumor of the pancreas: a case report. Int J Surg Pathol.
2007;15:311–314.
10. Vennarecci G, Ettorre GM, Giovannelli L, et al. Solitary fibrous
tumor of the liver. J Hepatobiliary Pancreat Surg. 2005;12:341–344.
11. Langman G. Solitary fibrous tumor: a pathological enigma and
clinical dilemma. J Thorac Dis. 2011;3:86–87.
12. Rao N, Colby TV, Falconieri G, et al. Intrapulmonary solitary
fibrous tumors: clinicopathologic and immunohistochemical study of
24 cases. Am J Surg Pathol. 2013;37:155–166.
13. Mohammed AlShati H. Solitary fibrous tumour of the pleura: a
moving target. Can Respir J. 2014;21:145.
7/3 6/14 4/16 2/18 3/17 0/2014. Liu bbY, Tao X, Shi H, et al. MRI findings of solitary fibrous
tumours in the head and neck region. Dentomaxillofac Radiol.
2014;43:20130415.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
15. de Perrot M, Fischer S, Bru¨ndler MA, et al. Solitary fibrous tumors
of the pleura. Ann Thorac Surg. 2002;74:285–293.
16. Thorgeirsson T, Isaksson HJ, Hardardottir H, et al. Solitary fibrous
tumors of the pleura: an estimation of population incidence. Chest.
2010;137:1005–1006.
17. England D, Hochholzer L, McCarthy M. Localized benign and
malignant fibrous tumors of the pleura: a clinicopathologic review of
223 cases. Am J Surg Pathol. 1989;13:640–658.
18. Papathanassiou ZG, Alberghini M, Picci P, et al. Solitary fibrous
tumors of the soft tissues: imaging features with histopathologic
correlations. Clin Sarcoma Res. 2013;3:1.
19. Xiao Y, Jiang Q, Bingbing YU. Solitary fibrous tumor located in the
sella turcica: a report of two cases and review of the literature.
Oncol Lett. 2015;10:354–358.
20. Wignall OJ, Moskovic EC, Thway K, et al. Solitary fibrous tumors
of the soft tissues: review of the imaging and clinical features with
histopathologic correlation. AJR Am J Roentgenol. 2010;195:W55–62.
21. Zhang WD, Chen JY, Cao Y, et al. Computed tomography and
magnetic resonance imaging findings of solitary fibrous tumors in
the pelvis: correlation with histopathological findings. Eur J Radiol.
2011;78:65–70.
Medicine  Volume 95, Number 13, April 2016solitary fibrous tumor of the abdominopelvic cavity. J Comput Assist
Tomogr. 2010;34:201–205.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.23. Xue-Ming Li, Jing Reng, Peng Zhou, et al. Solitary fibrous tumors
in abdomen and pelvis: imaging characteristics and radiologic-
pathologic correlation. World J Gastroenterol. 2014;20:5066–5073.
24. Chun HJ, Byun JY, Jung SE, et al. Benign solitary fibrous tumour of
the pre-sacral space: MRI findings. Br J Radiol. 1998;71:677–679.
25. Tanaka M, Sawai H, Okada Y, et al. Malignant solitary fibrous
tumor originating from the peritoneum and review of the literature.
Med Sci Monit. 2006;12:CS95–CS98.
26. Zhao G, Li G, Han R. Two malignant solitary fibrous tumors in one
kidney: case report and review of the literature. Oncol Lett.
2012;4:993–995.
27. Khandelwal A, Virmani V, Amin MS, et al. Radiology-pathology
conference: malignant solitary fibrous tumor of the seminal vesicle.
Clin Imaging. 2013;37:409–413.
28. Levard A, Derbel O, Me´eus P, et al. Outcome of patients with
advanced solitary fibrous tumors: the Centre Le´on Be´rard experi-
ence. BMC Cancer. 2013;13:109.
29. Liu Y, Li K, Shi H, et al. Solitary fibrous tumours in the extracranial
head and neck region: correlation of CT and MR features with
pathologic findings. Radiol Med. 2014;119:910–919.
30. Meroni S, Funicelli L, Rampinelli C, et al. Solitary fibrous tumours:
CT and MR Imaging Features of SFTsunusual aspects of a rare disease. Hippokratia. 2012;16:269–274.22. Rosenkrantz AB, Hindman N, Melamed J. Imaging appearance of31. Clarenc¸on F, Bonneville F, Rousseau A, et al. Intracranial solitary
fibrous tumor: imaging findings Eur J Radiol. 2011;80:387–394.
www.md-journal.com | 7
